Building a leading lymphoma portfolio by evolving our research for patients with indolent NHL
Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) are two types in a class of slow-growing B-cell cancers referred to as indolent non-Hodgkin’s Lymphomas (iNHLs), which are primarily slow-growing, exhibit extremely variable outcomes and still remain incurable. They have been shown to develop most frequently in older adults and in individuals who are immunocompromised.
The iNHL therapeutic standard of care is immunochemotherapy consisting of traditional chemotherapy combined with an anti-CD20 monoclonal antibody. Despite initially achieving good responses, most patients with iNHL will relapse and will experience multiple relapses that require multiple rounds of therapeutic intervention. Durability of responses has been shown to diminish with each line of therapy. Therefore, patients may experience a prolonged disease course (up to 10 or more years) and multiple relapses.
Celgene is a pioneer in developing novel therapies for treatment of hematologic malignancies. Based on an our improved understanding of iNHL disease biology, we are challenging the Chemotherapy-based standard of care by exploring chemotherapy-free options that seek to address the underlying immune dysfunction that drives and contributes to this class of diseases.
Advocacy & Collaboration
Learn about various relationships and collaborations that help drive innovation in iNHL:
Celgene remains committed to continue addressing the needs of patients with indolent NHL by exploring novel and chemotherapy-free mechanisms with a goal of improving lives of patients with this disease.
Resources are under development. Check back here for updates.